A COVID-19 vaccine candidate being produced by biotech company Moderna has shown to be 94.5% effective in Phase 3 clinical trials, the company said Monday.
The news means that the company is on track to request Emergency Use Authorization status for the drug in the coming weeks.
The vaccine is already being mass-produced and thousands of doses will be ready to ship following authorization.
The release comes a week after Pfizer announced its own vaccine candidate was also on track for mass distribution after showing 90% effectiveness in Phase 3 trials.
Both Moderna and Pfizer are on track to seek permission for emergency use in the U.S. within weeks. Still, initial supplies will be limited and rationed.
The announcements come as the virus surges in the U.S. and around the world.